ArticleInternational orthopaedics2021
Pulmonary metastasis of giant cell tumour: a retrospective study of three hundred and ten cases.
Article in International orthopaedics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- De novo osteosarcoma following prolonged denosumab treatment for giant cell tumor of bone at an anatomically distant site: a case report.Skeletal radiology · 2026Article
- ICG-based NIR fluorescence imaging can help to detect residual giant cell tumor of bone after intralesional curettage: Results of two-year follow-up.Journal of bone oncology · 2026Article
- Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A.Biomedicines · 2026Review
- Pulmonary metastasis of giant cell tumor of bone 29 years after local recurrence resection: implications for Long-Term surveillance.Discover oncology · 2025Article
- 30 YEARS OF BONE GIANT CELL TUMOR IN THE KNEE: A BRAZILIAN PERSPECTIVE.Acta ortopedica brasileira · 2025Article
- UK guidelines for the management of bone sarcomas.British journal of cancer · 2025Review
- Management and surveillance of metastatic giant cell tumour of bone.Pathology oncology research : POR · 2025Article
- Article
- Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update.Current oncology (Toronto, Ont.) · 2024Review
- A case report on pulmonary metastasis of giant cell tumor mimicking arteriovenous malformation.Radiology case reports · 2024Article
- GIANT CELL TUMOR OF BONE: A MULTICENTER EPIDEMIOLOGICAL STUDY IN BRAZIL.Acta ortopedica brasileira · 2024Article
- Non‑surgical outcomes and risk factors for pulmonary metastasis from giant cell tumor of bone.Oncology letters · 2023Article
- How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?International orthopaedics · 2022Article
- Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone.Human cell · 2021Article
- Risk factors and oncological outcomes of pulmonary metastasis in patients with giant cell tumor of bone.Journal of clinical orthopaedics and trauma · 2021Article
- Review
- Multiple Pulmonary Metastases of Recurrent Giant Cell Tumor of Bone with Expression of VEGFR-2 Successfully Controlled by Denosumab and Apatinib: A Case Report and Literature Review.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell tumour (GCT) is an invasive benign bone tumour, and the incidence of pulmonary metastasis is rare. We are aiming to analyze risk factors of pulmonary metastasis and clinical prognosis for giant cell tumour patients with pulmonary metastasis.
methodWe performed a retrospective study of 310 patients with GCT between December 2004 and December 2016. Risk factors of pulmonary metastasis were analyzed by univariate and multivariate logistic regression analysis. Then, the influence of risk factors of overall LR (local recurrence), recurrent tumor at presentation, LR after our therapy, and with soft tissue mass on the pulmonary metastasis-free survival rates was analyzed.
resultsThe mean follow-up of the present cohort was 45.6 ± 35.3 months (median, 36.6 months; range, 6.1-193.4 months). Eighteen (5.8%) of 310 patients developed pulmonary metastasis. The average interval from surgery of primary tumour to detection of pulmonary metastasis was 15 months. Multivariate logistic regression analysis showed overall local recurrence was the independent risk factor of developing pulmonary metastasis. Among 18 patients with pulmonary metastasis, sixteen cases had history of local recurrence (88.9%, 16/18), including eleven (68.8%, 11/16) with local recurrence at presentation before receiving our therapy and seven (43.8%, 7/16) with local recurrence after receiving treatment in our hospital. Time to local recurrence had obvious difference between patients with and without pulmonary metastasis. Patients with pulmonary metastasis were prone to recur earlier. Furthermore, overall local recurrence, local recurrence after our therapy, recurrent tumor at presentation, and tumour with a soft tissue mass showed statistical differences in the pulmonary metastasis-free survival rates.
conclusionsGiant cell tumour patients with soft tissue mass and overall local recurrence are prone to develop pulmonary metastasis. Although giant cell tumour is a benign tumor, more attention should be paid to the problem of pulmonary metastatic lesions, and chest CT scan should be recommended during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.